These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 1442812)
1. Changes in FDA drug classification and priority review policy. Crawford SY Am J Hosp Pharm; 1992 Oct; 49(10):2383, 2386. PubMed ID: 1442812 [No Abstract] [Full Text] [Related]
2. FDA drug classification system. Sanborn MD; Godwin HN; Pessetto JD Am J Hosp Pharm; 1991 Dec; 48(12):2659-62. PubMed ID: 1814217 [TBL] [Abstract][Full Text] [Related]
3. New office and new leader aim to streamline FDA cancer drug review process. Twombly R J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036 [No Abstract] [Full Text] [Related]
4. The FDA's drug review process: ensuring drugs are safe and effective. Meadows M FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298 [No Abstract] [Full Text] [Related]
5. FDA restructures new product review centers. Bouchie A Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100 [No Abstract] [Full Text] [Related]
6. Teaching the elephant to dance: privatizing the FDA review process. Price EC Food Drug Law J; 1996; 51(4):651-76. PubMed ID: 11797734 [No Abstract] [Full Text] [Related]
7. FDA finds new ways to speed treatment to patients. Flieger K FDA Consum; 1993 Oct; 27(8):14-8. PubMed ID: 10129048 [No Abstract] [Full Text] [Related]
8. TransMolecular receives FDA approval for 131-I-TM-601 IND application. Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233 [No Abstract] [Full Text] [Related]
9. FDA not NIH can speed new drugs. Miller HI Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657 [No Abstract] [Full Text] [Related]
10. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked? Shulman SR; Brown JS Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017 [No Abstract] [Full Text] [Related]
11. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy? Lovell MC Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202 [No Abstract] [Full Text] [Related]
13. Food and Drug Administration approval process for ophthalmic drugs in the US. Lloyd R; Harris J; Wadhwa S; Chambers W Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492 [TBL] [Abstract][Full Text] [Related]
14. Communicating with the FDA: the "third rail" of a new model for drug development. Stanski DR; Orloff JJ J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890 [No Abstract] [Full Text] [Related]
15. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity. Fernandez DS; Huie JT Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155 [No Abstract] [Full Text] [Related]
16. Investigational drug tracking: phases I-III and NDA submissions--Part II. Grant KL Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850 [TBL] [Abstract][Full Text] [Related]
17. Overhaul at the FDA begins. Science; 1992 Apr; 256(5055):313. PubMed ID: 1566081 [No Abstract] [Full Text] [Related]
18. A critical tipping point. Zuckerman MB US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366 [No Abstract] [Full Text] [Related]
19. A Food and Drug Administration primer. Simon LS Arthritis Rheum; 2006 Feb; 55(1):4-8. PubMed ID: 16463403 [No Abstract] [Full Text] [Related]